Literature DB >> 9792077

Evaluation of drug efficacy by using animal models or in vitro systems.

M Brun Pascaud1, E Herreros, E M Aliouat, E Dei-Cas.   

Abstract

The efficacy of most therapeutic and prophylactic protocols against Pneumocystis carinii pneumonia used in human patients has been tested in animal models, especially in the corticosteroid-treated rat. The advantages and drawbacks of this model have been examined in brief in Chapter 1 of this section. More recently, the nude rat, intratracheally inoculated with Pneumocystis, was used to test new anti-microbian molecules for their anti-Pneumocystis activity. In vitro systems, co-cultures of Pneumocystis with feeder cells as well as axenic cultures, were also used many times for drug screening. In this paper, the most used in vivo or in vitro drug screening systems are described. Moreover, as immunocompromised individuals, AIDS patients, especially, are often infected simultaneously by several infectious agents, a recent co-infection model is described.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792077     DOI: 10.1111/j.1574-695X.1998.tb01203.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  3 in total

1.  Phylogeny of Pneumocystis carinii from 18 primate species confirms host specificity and suggests coevolution.

Authors:  C Demanche; M Berthelemy; T Petit; B Polack; A E Wakefield; E Dei-Cas; J Guillot
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

2.  Antifungal activities and cytotoxicity studies of six new azasordarins.

Authors:  E Herreros; M J Almela; S Lozano; F Gomez de las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  SYTO-13, a Viability Marker as a New Tool to Monitor In Vitro Pharmacodynamic Parameters of Anti-Pneumocystis Drugs.

Authors:  Annie Standaert-Vitse; Cécile-Marie Aliouat-Denis; Anna Martinez; Sara Khalife; Muriel Pottier; Nausicaa Gantois; Eduardo Dei-Cas; El Moukhtar Aliouat
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.